Several other brokerages have also recently issued reports on NOVN. Piper Jaffray Cos. started coverage on Novan in a research note on Monday. They issued an overweight rating and a $25.00 price objective on the stock. Wedbush started coverage on Novan in a research note on Monday. They issued an outperform rating and a $27.00 price objective on the stock.
Novan (NASDAQ:NOVN) traded up 3.17% on Monday, hitting $21.18. The stock had a trading volume of 18,530 shares. The firm’s market cap is $51.83 million. Novan has a 52-week low of $13.77 and a 52-week high of $23.79. The company has a 50-day moving average price of $19.83 and a 200 day moving average price of $19.83.
In related news, major shareholder Life Sciences Holdings L. Malin bought 800,000 shares of the company’s stock in a transaction on Monday, September 26th. The shares were acquired at an average price of $11.00 per share, with a total value of $8,800,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).
Receive News & Ratings for Novan Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan Inc and related companies with MarketBeat.com's FREE daily email newsletter.